

**October 29, 2018**

To,  
Department of Corporate Services  
**BSE Limited**  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001  
Scrip Code: **BSE - 524500**

To,  
Corporate Listing Department  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051  
Scrip Code: **NSE - KILITCH**

Dear Sirs,

**Sub: Statement of Deviation or Variation under Regulation 32 of the SEBI  
(Listing Obligation and Disclosure Requirement) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 32 (1) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, we submit that during the quarter ended 30<sup>th</sup> September, 2018 there is no deviation in use of the proceeds aggregating to Rs. 7,08,00,000/- (75% of the issue price of the warrants) received from respective warrant holders on issue and allotment of 1600000 equity shares on conversion of warrants issued on preferential basis in pursuance of the approval of shareholders.

The above is for your information and dissemination to the members.

Thanking you,

Yours Faithfully,  
For **Kilitch Drugs (India) Limited**

  
**Mukund Mehta**  
**Managing Director**  
**(DIN:00147876)**

